Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Analysis: Small caps set to keep surging as vaccines aid recovery

11/30/2020 | 11:40am EST
The U.S. flag is seen on a building on Wall St. in the financial district in New York

NEW YORK (Reuters) - Small cap stocks have far outperformed their larger counterparts in November en route to their best monthly performance on record, and look set to remain Wall Street leaders as companies poised to benefit from an economic recovery.

The Russell 2000 and S&P 600 indexes of small cap stocks are up more than 19% for the month - the biggest monthly percentage jump for both indexes, which date back to 1979 and the end of 1993, respectively - as investors bet recent positive trial results for COVID-19 vaccines will help pull the economy out of a recession.

While smaller names typically see outsized price moments compared to their larger brethren, the small cap gains for November have nearly doubled the roughly 11% gain in the S&P 500 this month.

Mega cap work-from-home leaders like Amazon.com and Netflix Inc that have benefited from COVID-19 economic restrictions had helped the S&P 500 outperform smaller names since the pandemic lows in March. But they have begun to lag of late as optimism grows that highly effective vaccines will soon be available.

On Monday, Moderna Inc said it would seek U.S. and European emergency authorization for its vaccine after full results from a late-stage study showed it to be 94.1% effective in preventing COVID-19, joining Pfizer Inc in applying for emergency use.

"As you got this vaccine news you started to get this rotation into the reopening side of the economy into small cap stocks, value stocks," said Tom Hainlin from global investment strategist U.S. Bank Wealth Management's Ascent Private Wealth Group in Minneapolis.

Small cap stocks are generally seen as the first to recover as the U.S. economy pulls out of a recession. They rely less on overseas revenue and are advantaged by a heavy concentration in cyclical sectors such as financials, materials, energy and industrials that also do well as an economy begins to expand.

"You've got a lot more domestic exposure, you have an economy doing better, that is going to work well," said Steven DeSanctis, equity strategist at Jefferies in New York.

According to FTSE Russell, as of Sept. 30, economically sensitive financials, industrials, materials and energy accounted for 36% of the weighting in the Russell 2000 index. In the S&P 600, those four sectors account for more than 43% of the total index weighting, per Refinitiv data. In the large cap S&P 500, the same four sectors account for about 24.5% of the overall index weighting.

DeSanctis noted that even with the recent surge in smaller stocks, they are still below their long-term performance trend relative to the large cap S&P 500, giving them room to climb.

Graphic: 20-year performance of Russell to S&P 500

In addition, small caps appear comparatively cheap, even with the strong November performance. In a recent note to clients, Keith Lerner, chief market strategist at Truist/Suntrust Advisory Services in Atlanta points out the S&P 600 is trading at a discount relative to the S&P 500 on a number of valuation metrics, including price to earnings, price to sales and price to cash flow.

Graphic: Small cap price to earnings relative to large cap

While the longer economic outlook may be positive, the next few months are expected to be rocky, which could lead to some volatility for small caps. JPMorgan analyst Michael Feroli recently forecast an economic contraction of a 1% annualized rate in the first quarter, down from the prior view of a 1.5% increase.

Recent economic data has been uneven, showing a slowing in the labor market and a drop in income, while spending on both the consumer and business side has held up. In their November policy meeting, Federal Reserve officials discussed how the central bank's asset purchases could be adjusted to provide more support to markets and the economy.

"It's not a perfect backdrop but if you look through to the second half of 2021, you can see things doing a lot better," said DeSanctis.

While markets and the economy may stall in the near-term, investors should not mistake that for a double-dip recession, said Morgan Stanley Wealth Management Chief Investment Officer Lisa Shalett, who noted upward earnings revisions for the Russell 2000 are at a 20-year high and "such a development has typically augured well for a full economic recovery."

November has historically been the best month for the Russell 2000, however, December typically yields the second-best monthly performance, according to Sam Stovall, chief investment strategist at CFRA Research in New York.

The Russell 2000 averages a 2.15% return in December, climbing 76% of the time for the highest frequency of advance, compared to an average gain of 1.47% for the S&P 500 and a 73% frequency of advance, Stovall noted.

(Reporting by Chuck Mikolajczak; Editing by Alden Bentley and Bill Berkrot)

By Chuck Mikolajczak

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.52% 30974.81 Delayed Quote.0.68%
JPMORGAN CHASE & CO. 0.00% 138.58 Delayed Quote.9.11%
MODERNA, INC. -4.93% 123.3301 Delayed Quote.24.10%
MORGAN STANLEY 0.20% 75.38 Delayed Quote.9.79%
NASDAQ 100 1.45% 12989.151398 Delayed Quote.-0.65%
NASDAQ COMP. 1.46% 13188.62378 Delayed Quote.0.86%
NETFLIX, INC. 1.09% 503.505 Delayed Quote.-7.91%
PFIZER INC. 0.07% 36.725 Delayed Quote.-0.30%
S&P 500 0.91% 3802.43 Delayed Quote.0.32%
All news about MODERNA, INC.
01:43pASTRAZENECA : India to start COVID vaccine exports on Wednesday
01:37pASTRAZENECA : India to start COVID vaccine exports on Wednesday
01:25pMODERNA : says possible allergic reactions to COVID-19 vaccine under investigati..
12:46pMODERNA : receives report of COVID-19 vaccine adverse events in San Diego
12:36pMODERNA : Statement on California Department of Public Health (CDPH) Report
11:35aBrussels targets vaccinating at least 70% of EU adults by summer
11:15aMODERNA : EU commission urges member states to speed up vaccination
09:11aMODERNA : New York governor asks Pfizer to directly sell COVID-19 vaccine doses
07:31aJapan has pre-ordered COVID-19 vaccine doses for more than four times its pop..
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 -561 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -107x
Yield 2020 -
Capitalization 51 304 M 51 304 M -
EV / Sales 2020 95,2x
EV / Sales 2021 4,38x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 136,60 $
Last Close Price 129,65 $
Spread / Highest target 42,7%
Spread / Average Target 5,36%
Spread / Lowest Target -46,8%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.10%51 304
LONZA GROUP AG2.46%48 618
CELLTRION, INC.-12.95%38 786
SEAGEN INC.6.06%33 601